« Return to News | Awards & Advancement

BioHealth names Chappell first entrepreneur-in-residence

Tuesday, March 27, 2012 06:01 AM

BioHealth Innovation (BHI), a new regional private-public partnership, has selected Todd Chappell as the first entrepreneur-in-residence for BHI at the National Institutes of Health (NIH) Office of Technology Transfer (OTT).

Chappell is a venture capital-backed entrepreneurial leader and inventor with more than 10 years of experience in molecular biology research, drug development and life sciences business strategy. Before coming to BHI, he served as the vice president of operations at venture-capital backed Shape Pharmaceuticals, and prior to that he spent nine years at CombinatoRx as director of new products.

As the first entrepreneur-in-residence, Chappell—who will have dual responsibility to both BHI and NIH—will assist OTT in the evaluation of existing technologies, provide an entrepreneurial perspective to OTT in its evaluation of new licensing proposals from start-up companies, advise OTT on opportunities for new ventures based on NIH/FDA technologies, assist with developmental strategies and mentor scientists to help ensure their research becomes commercially valuable.

"There is tremendous start-up potential coming from the 27 institutes of NIH and the FDA research labs,” said Chappell. “With the right strategies and management, new entrepreneurial ventures will be created, and with them, new research, technology and commercially viable health care solutions."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.